Surgically resectable oesophageal adenocarcinoma deemed suitable for surgery and neoadjuvant/adjuvant chemotherapy research hub

A clinical trial assessing the safety, tolerability and anti-tumour activity of the ITOP1 vaccination in patients with surgically resectable oesophageal adenocarcinoma

This study is testing a new 'vaccine' (ITOP1) for oesophageal cancer. It aims to stop cancer from returning after surgery and chemotherapy by training the body's immune system. Researchers will check if it's safe and if it helps prevent the cancer from coming back.